Laurus Labs is currently trading at RS. 893.15, up by 55.10 points or 6.57% from its previous closing of RS. 838.05 on the BSE.

The stock opened at RS. 834.00 and has touched an intraday high of RS. 901.00 and a low of RS. 827.95. A total of 7,86,220 shares have been traded so far.

Classified under BSE group 'A', the stock with a face value of RS. 2 has hit a 52-week high of RS. 901.00 on July 28, 2025, and a 52-week low of RS. 390.30 on August 8, 2024. Over the past week, the scrip has recorded a high of RS. 901.00 and a low of RS. 815.05. The company’s current market capitalization stands at RS. 48244.31 crore.

The promoter holding in Laurus Labs is 27.59%, while institutional and non-institutional investors hold 37.64% and 34.78% respectively.

In a major development, Laurus Labs has received 531.77 acres of land from the Government of Andhra Pradesh in IP Rambilli Phase-II of Anakapalli. The land will be used to establish the Laurus Pharma Zone (LPZ) aimed at setting up pharmaceutical manufacturing units.

The company has planned an investment of RS. 5630 crore for this project, expected to create employment for around 6,350 people over three phases in the next eight years. This land acquisition marks a critical step in Laurus Labs’ long-term expansion strategy.

Laurus Labs is a leading R&D-driven pharmaceutical company in India, known for its strong presence in manufacturing active pharmaceutical ingredients (APIs) for anti-retroviral (ARV), Hepatitis C, oncology, and other therapeutic segments.